<DOC>
	<DOCNO>NCT01874054</DOCNO>
	<brief_summary>The purpose study assess safety efficacy brentuximab vedotin combination bendamustine patient relapse refractory Hodgkin lymphoma . It open-label , 2-stage study design determine recommend dose level bendamustine combination brentuximab vedotin . The study assess safety profile combination treatment determine proportion patient achieve complete remission .</brief_summary>
	<brief_title>Study Brentuximab Vedotin Combined With Bendamustine Patients With Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histopathological diagnosis classical Hodgkin lymphoma Failed standard frontline therapy Measurable disease least 1.5 cm document radiographic technique Eastern Cooperative Oncology Group performance status less equal 2 Received prior salvage therapy , include radiotherapy Chemotherapy , radiotherapy , biologics , and/or treatment immunotherapy complete 4 week prior first dose study drug Concurrent use investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Hodgkin Disease</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>monomethylauristatin E</keyword>
</DOC>